Serum interleukin-8 levels may predict relapse in brucellosis
Serum interleukin-8 levels may predict relapse in brucellosis
复制标题
血清白介素 8 水平可预测布鲁氏菌病复发
DOI：
10.3906/sag-1107-60
复制
发表时间：
2012
影响因子：
2.3
通讯作者：
O. Ural
中科院分区：
文献类型：
--
作者：
N. Demi̇r;O. Ural
探讨细胞因子是否能有效预测急性布鲁氏菌病患者的复发。材料和方法：本试验在42例正在随访的急性布鲁氏菌病患者中进行。在第0天和第45天获得血清样品。在治疗一年内临床症状复发并表现出符合布鲁氏菌病感染参数的患者中，进行了Rivanol标准试管凝集（STA）试验，并根据布鲁氏菌免疫球蛋白M（IgM）诊断复发。评价血清样品的各种参数，即肿瘤坏死因子-α（TNF-α）、干扰素-γ（IFN-γ）、白细胞介素2（IL-2）、IL-4、IL-6、IL-8、IL-10和可溶性IL-2受体（sIL-2 R）。结果：7例患者复发。复发患者（RP）和完全恢复患者（FRP）在年龄、性别、白细胞水平或C反应蛋白（CRP）值方面无差异。比较第0天（入组当天）的TNFa、IFNg、IL-2、IL-4、IL-6、IL-8和IL-10值，显示RP中的IL-8值是FRP的2倍。IL-8在预测复发方面具有重要意义。结论：急性布鲁氏菌病复发病例的诊断和治疗尚未明确。通过某些实验室评估预测复发可能有利于通过重新安排患者的治疗和监测策略来预防临床复发。
To investigate whether cytokines are effective in predicting relapses among patients with acute brucellosis. Materials and methods: This trial was conducted in 42 patients who were being followed-up with diagnosis of acute brucellosis. Serum samples were obtained on days 0 and 45. In patients whose clinical symptoms recurred within a year of treatment and exhibited infectious parameters in compliance with brucellosis, a Rivanol standard tube agglutination (STA) test was performed and the diagnosis of relapse was based on brucella immunoglobulin M (IgM). Serum samples were evaluated for various parameters, namely tumor necrosis factor-alpha (TNF-a), interferon-gamma (IFN-g), interleukin 2 (IL-2), IL-4, IL-6, IL-8, IL-10, and soluble IL-2 receptor (sIL-2R). Results: Relapse was seen in 7 patients. No difference was found between relapsing patients (RPs) and fully recovered patients (FRPs) in terms of age, sex, leukocyte levels, or C-reactive protein (CRP) values. Comparison of TNFa, IFNg, IL-2, IL-4, IL-6, IL-8, and IL-10 values on day 0 (day of enrollment) revealed 2-fold higher IL-8 values among RPs compared to FRPs. IL-8 was suggested as significant in terms of predicting relapse. Conclusion: Diagnosis and treatment of relapsing cases in acute brucellosis have not yet been clarified. Predicting relapse by certain laboratory evaluations may be beneficial in preventing clinical relapses by rearranging treatment and monitoring strategies of patients.